Macrolides for diffuse panbronchiolitis

The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms

“…Indeed, clinically beneficial effects have been shown in randomized controlled studies in patients with COPD and CF with improved symptom scores, respiratory function and decreased frequency of exacerbations ( 67 – 69 ). For DPB, bronchiectasis and asthma, however, there is an absence of randomized controlled studies showing clinical beneficial effects of macrolides ( 70 – 72 ).…”

The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms

“…Indeed, clinically beneficial effects have been shown in randomized controlled studies in patients with COPD and CF with improved symptom scores, respiratory function and decreased frequency of exacerbations ( 67 – 69 ). For DPB, bronchiectasis and asthma, however, there is an absence of randomized controlled studies showing clinical beneficial effects of macrolides ( 70 – 72 ).…”

Is bronchiectasis really a disease?

“…Therapeutic modalities with established efficacy in bronchiectasis are also far from specific and beneficial in other airway diseases. Macrolides have proven efficacy in reducing exacerbations in CF [101], but also in diffuse panbronchiolitis [102,103], bronchiolitis obliterans in lung transplant recipients [104][105][106], COPD [107][108][109], CRS [110] and, recently, asthma [111]. Airway clearance and inhaled mucolytic agents, such as hypertonic saline, are the first-line treatment for CF [112].…”

Long-term macrolide maintenance therapy in non-CF bronchiectasis: Evidence and questions

“…In addition to the immunomodulatory properties of macrolides, there is a sound scientific rationale for studying these agents in non-CF bronchiectasis, based on their beneficial clinical effects including controlling exacerbations in patients with CF [28], COPD [29] and diffuse panbronchiolitis [26,30]. The small number of reports published before 2012 had limitations [14e19, 21,23].…”

The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms

“…Indeed, clinically beneficial effects have been shown in randomized controlled studies in patients with COPD and CF with improved symptom scores, respiratory function and decreased frequency of exacerbations ( 67 – 69 ). For DPB, bronchiectasis and asthma, however, there is an absence of randomized controlled studies showing clinical beneficial effects of macrolides ( 70 – 72 ).…”

Is bronchiectasis really a disease?

“…Therapeutic modalities with established efficacy in bronchiectasis are also far from specific and beneficial in other airway diseases. Macrolides have proven efficacy in reducing exacerbations in CF [101], but also in diffuse panbronchiolitis [102,103], bronchiolitis obliterans in lung transplant recipients [104][105][106], COPD [107][108][109], CRS [110] and, recently, asthma [111]. Airway clearance and inhaled mucolytic agents, such as hypertonic saline, are the first-line treatment for CF [112].…”

Long-term macrolide maintenance therapy in non-CF bronchiectasis: Evidence and questions

“…In addition to the immunomodulatory properties of macrolides, there is a sound scientific rationale for studying these agents in non-CF bronchiectasis, based on their beneficial clinical effects including controlling exacerbations in patients with CF [28], COPD [29] and diffuse panbronchiolitis [26,30]. The small number of reports published before 2012 had limitations [14e19, 21,23].…”

The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms

“…Indeed, clinically beneficial effects have been shown in randomized controlled studies in patients with COPD and CF with improved symptom scores, respiratory function and decreased frequency of exacerbations ( 67 – 69 ). For DPB, bronchiectasis and asthma, however, there is an absence of randomized controlled studies showing clinical beneficial effects of macrolides ( 70 – 72 ).…”

Is bronchiectasis really a disease?

“…Therapeutic modalities with established efficacy in bronchiectasis are also far from specific and beneficial in other airway diseases. Macrolides have proven efficacy in reducing exacerbations in CF [101], but also in diffuse panbronchiolitis [102,103], bronchiolitis obliterans in lung transplant recipients [104][105][106], COPD [107][108][109], CRS [110] and, recently, asthma [111]. Airway clearance and inhaled mucolytic agents, such as hypertonic saline, are the first-line treatment for CF [112].…”

Long-term macrolide maintenance therapy in non-CF bronchiectasis: Evidence and questions

“…In addition to the immunomodulatory properties of macrolides, there is a sound scientific rationale for studying these agents in non-CF bronchiectasis, based on their beneficial clinical effects including controlling exacerbations in patients with CF [28], COPD [29] and diffuse panbronchiolitis [26,30]. The small number of reports published before 2012 had limitations [14e19, 21,23].…”